These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 22671928)

  • 1. Novel targets and derived small molecule inhibitors in multiple myeloma.
    Podar K
    Curr Cancer Drug Targets; 2012 Sep; 12(7):797-813. PubMed ID: 22671928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches.
    Kizaki M; Tabayashi T
    J Clin Exp Hematop; 2016; 56(1):20-7. PubMed ID: 27334854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging therapies for multiple myeloma.
    Podar K; Tai YT; Hideshima T; Vallet S; Richardson PG; Anderson KC
    Expert Opin Emerg Drugs; 2009 Mar; 14(1):99-127. PubMed ID: 19249983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
    Palumbo A; Sonneveld P
    Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
    Podar K; Jager D
    Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of myeloma: an Italian perspective.
    Bruno B; Gay F; Boccadoro M; Palumbo A
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S82-6. PubMed ID: 22035755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma.
    Neri P; Bahlis NJ
    Curr Cancer Drug Targets; 2012 Sep; 12(7):776-96. PubMed ID: 22671924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel therapies in MM: from the aspect of preclinical studies.
    Hideshima T; Anderson KC
    Int J Hematol; 2011 Oct; 94(4):344-354. PubMed ID: 21881879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple myeloma: Implementing signaling pathways and molecular biology in clinical trials.
    Bazzi M; Badros A
    Cancer Biol Ther; 2010 Nov; 10(9):830-8. PubMed ID: 21045554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
    Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T
    Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
    Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the management of multiple myeloma.
    Munshi NC
    Semin Hematol; 2004 Apr; 41(2 Suppl 4):21-6. PubMed ID: 15190512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
    Bladé J; Cibeira MT; Rosiñol L
    Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
    Shay G; Hazlehurst L; Lynch CC
    J Mol Med (Berl); 2016 Jan; 94(1):21-35. PubMed ID: 26423531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide in multiple myeloma.
    Richardson PG; Mitsiades C; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging role of novel combinations for induction therapy in multiple myeloma.
    Voorhees PM; Orlowski RZ
    Clin Lymphoma Myeloma; 2006 Jul; 7(1):33-41. PubMed ID: 16879768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of thalidomide in the treatment of multiple myeloma].
    Mikala G; Jákó J; Vályi-Nagy I
    Orv Hetil; 2001 Aug; 142(33):1789-98. PubMed ID: 11573449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daratumumab granted breakthrough drug status.
    Laubach JP; Tai YT; Richardson PG; Anderson KC
    Expert Opin Investig Drugs; 2014 Apr; 23(4):445-52. PubMed ID: 24555809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contemporary drug therapies for multiple myeloma.
    de la Puente P; Azab AK
    Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.
    Vallet S; Podar K
    Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S35-53. PubMed ID: 23768134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.